A composition, comprising a hydrogel matrix and microparticles within said matrix, said matrix comprising a cross-linkable protein and a cross-linking agent, wherein said cross-linking agent is able to cross-link said cross-linkable protein, wherein said microparticles comprise a drug.

A composition, comprising a hydrogel matrix and microparticles within said matrix, said matrix comprising a cross-linkable protein and a cross-linking agent, wherein said cross-linking agent is able to cross-link said cross-linkable protein, wherein said microparticles comprise a drug.

The invention concerns a bone graft material for use in a spinal fusion method, wherein the material comprises i) a composition for forming a matrix, comprising at least a first matrix material precursor component and a second matrix material precursor component, capable of forming a matrix by crosslinking of the precursor components under appropriate conditions; and ii) a bioactive factor, which is biologically active to stimulate bone formation between two vertebrae, and for effecting or supporting spinal fusion; wherein the spinal fusion method comprises the steps of applying a cage in between the two vertebrae, which is not pre-filled with the bone graft material; and subsequently applying the bone graft material adjacent to and/or into the cage, such that essentially the entire remaining volume between the two vertebrae is filled with the bone graft material. The invention allows for ease of use while forming a more homogeneous matrix.

The invention concerns a bone graft material for use in a spinal fusion method, wherein the material comprises i) a composition for forming a matrix, comprising at least a first matrix material precursor component and a second matrix material precursor component, capable of forming a matrix by crosslinking of the precursor components under appropriate conditions; and ii) a bioactive factor, which is biologically active to stimulate bone formation between two vertebrae, and for effecting or supporting spinal fusion; wherein the spinal fusion method comprises the steps of applying a cage in between the two vertebrae, which is not pre-filled with the bone graft material; and subsequently applying the bone graft material adjacent to and/or into the cage, such that essentially the entire remaining volume between the two vertebrae is filled with the bone graft material. The invention allows for ease of use while forming a more homogeneous matrix.

The present disclosure relates to a three-dimensional, degradable medical implant for regeneration of soft tissue comprising a plurality of volume-building components and a mesh component which is substantially made of monofilament or multifilament fibers, wherein each volume-building component is attached to at least one point on a surface of the mesh component, and wherein the projected surface area of each volume-building component, when projected on the surface of the mesh component, corresponds to a maximum of one tenth of the surface area of the mesh component.

The present disclosure relates to a three-dimensional, degradable medical implant for regeneration of soft tissue comprising a plurality of volume-building components and a mesh component which is substantially made of monofilament or multifilament fibers, wherein each volume-building component is attached to at least one point on a surface of the mesh component, and wherein the projected surface area of each volume-building component, when projected on the surface of the mesh component, corresponds to a maximum of one tenth of the surface area of the mesh component.

A hydrogel-based biological delivery vehicle used to effectively deliver drug and biological material to tissue or organ sites. More specifically, a hydrogel binding matrix having a biopolymer backbone containing carboxyl groups. Tyramine may be substituted for at least a portion of the carboxyl groups, so that, when hydrogen peroxide is added, it causes creation of covalent bonds between tyramine molecules and cross-links the hydrogel binding matrix, thereby enabling the hydrogel binding matrix to transition from liquid to gel state. The hydrogel binding matrix, in its liquid form, is capable of encapsulating drug reservoirs to create a homogenous liquid with evenly distributed particles containing drugs or target molecules. As the hydrogel binding matrix solidifies into a gel state, the newly created cross-links do not disrupt or react with the drugs or target molecules contained within the drug reservoirs. This hydrogel-based biological delivery vehicle can be used in several medical applications.

A hydrogel-based biological delivery vehicle used to effectively deliver drug and biological material to tissue or organ sites. More specifically, a hydrogel binding matrix having a biopolymer backbone containing carboxyl groups. Tyramine may be substituted for at least a portion of the carboxyl groups, so that, when hydrogen peroxide is added, it causes creation of covalent bonds between tyramine molecules and cross-links the hydrogel binding matrix, thereby enabling the hydrogel binding matrix to transition from liquid to gel state. The hydrogel binding matrix, in its liquid form, is capable of encapsulating drug reservoirs to create a homogenous liquid with evenly distributed particles containing drugs or target molecules. As the hydrogel binding matrix solidifies into a gel state, the newly created cross-links do not disrupt or react with the drugs or target molecules contained within the drug reservoirs. This hydrogel-based biological delivery vehicle can be used in several medical applications.

The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.

The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.